A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia.

Rafii MS, Skotko BG, McDonough MEllen, Pulsifer M, Evans C, Doran E, Muranevici G, Kesslak P, Abushakra S, Lott IT, et al.
J Alzheimers Dis. 2017; 58(2):401-411. PMID: 28453471. Abstract